{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:04Z","timestamp":1772119264893,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04730-z","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T02:37:29Z","timestamp":1733539049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)"],"prefix":"10.1007","volume":"95","author":[{"given":"Motohiro","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Makimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"issue":"2","key":"4730_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228","journal-title":"Lancet Oncol"},{"issue":"10","key":"4730_CR2","doi-asserted-by":"publisher","first-page":"e28398","DOI":"10.1002\/pbc.28398","volume":"67","author":"AC Winters","year":"2020","unstructured":"Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK (2020) Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer 67(10):e28398","journal-title":"Pediatr Blood Cancer"},{"key":"4730_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, Opferman JT, Rubnitz JE (2020) Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol 21:551\u2013560","journal-title":"Lancet Oncol"},{"key":"4730_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with Venetoclax in Relapsed Chronic lymphocytic leukemia. N Engl J Med 374:311\u2013322","journal-title":"N Engl J Med"},{"key":"4730_CR5","doi-asserted-by":"crossref","unstructured":"Yasu T, Gando Y, Nomura Y, Kosugi N, Kobayashi M (2022 Apr) Determination of Venetoclax Concentration in plasma using high-performance liquid chromatography. J Chromatogr Sci 5:bmac027","DOI":"10.1093\/chromsci\/bmac027"},{"issue":"15","key":"4730_CR6","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","volume":"116","author":"G Mann","year":"2010","unstructured":"Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R (2010) Interfant-99 Study Group. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 study. Blood 116(15):2644\u20132650","journal-title":"Blood"},{"issue":"3","key":"4730_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 27(3):377\u2013384","journal-title":"J Clin Oncol"},{"issue":"9","key":"4730_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00277-022-04871-2","volume":"101","author":"M Anzai","year":"2022","unstructured":"Anzai M, Yasu T, Gando Y, Shirota M, Kobayashi M (2022) Increased blood levels of venetoclax due to intake of crushed venetoclax tablets. Ann Hematol 101(9):2097\u20132098","journal-title":"Ann Hematol"},{"key":"4730_CR9","doi-asserted-by":"publisher","unstructured":"Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023 Apr) Pooled Population pharmacokinetic analyses of Venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol 13. https:\/\/doi.org\/10.1002\/jcph.2248","DOI":"10.1002\/jcph.2248"},{"issue":"1","key":"4730_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"Suppl 1","key":"4730_CR11","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood-2019-127803","volume":"134","author":"A Maiti","year":"2019","unstructured":"Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M et al (2019) Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II trial. Blood 134(Suppl 1):2637\u20132637","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04730-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04730-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04730-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T15:02:24Z","timestamp":1733583744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04730-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4730"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04730-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4212887\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state explicitly that there are no conflicts of interest in connection with this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}